RxDoctor Payments Data

Herma Baker, APRN

Family · Ocala, FLNPI 1770568339

Payments from drug & device makers

$345in general payments, 2019–2025

Across 12 payments — averaging $28.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$120
  • AbbVie$38
  • Harmony Biosciences LLC$32
  • Amgen$25
  • Xeris Pharmaceuticals, Inc.$23
  • Sunovion Pharmaceuticals Inc.$20
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$345 in reported general payments places this provider in the 45th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$25,429
Medicare patients
70
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$35,333
MounjaroTirzepatide25$26,852
OzempicSemaglutide16$22,175
TrulicityDulaglutide20$19,583
LinzessLinaclotide18$13,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$11,563
GemtesaVibegron12$9,203
Sucralfate19$2,898
Wixela InhubFluticasone Propion/Salmeterol26$2,395
Omeprazole83$1,980
Gabapentin90$1,520
Albuterol Sulfate HfaAlbuterol Sulfate46$1,323
Tresiba Flextouch U-100Insulin Degludec11$1,267
Baclofen51$1,014
Ibandronate Sodium48$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$38$13,63918 claims
GSKTrelegy Ellipta$120$11,56315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 14,618 family providers in Florida.

Other family in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →